Perindopril: ACE Inhibitor for Hypertension, Heart Failure and Cardiac Protection
Perindopril is a long-acting angiotensin-converting enzyme (ACE) inhibitor that is converted to its active form perindoprilat after oral administration. It is one of the most widely prescribed ACE inhibitors globally, particularly in Europe, where it has demonstrated cardiovascular outcome benefits beyond blood pressure lowering in patients with established coronary artery disease.
Perindopril is frequently combined with the diuretic indapamide in a fixed-dose combination, an evidence-based pairing supported by the ADVANCE and PROGRESS trials. The drug class effect of ACE inhibitor-related cough affects a significant proportion of patients and remains the most common reason for switching to an angiotensin receptor blocker (ARB).
Mechanism of Action
Perindopril is a prodrug that undergoes esterase-mediated conversion to perindoprilat, a potent competitive inhibitor of angiotensin-converting enzyme. ACE converts angiotensin I to the vasoconstrictor angiotensin II and also inactivates bradykinin. By blocking ACE, perindoprilat reduces angiotensin II levels (causing vasodilation and reduced aldosterone-mediated sodium retention) and allows bradykinin to accumulate (contributing to vasodilation but also to the characteristic cough). The antihypertensive effect results from peripheral vasodilation and decreased preload and afterload. Additional cardiovascular benefits include endothelial protection, anti-inflammatory effects, and prevention of vascular and myocardial remodelling.
Indications
Perindopril is approved for essential hypertension, heart failure with reduced ejection fraction (HFrEF), and stable coronary artery disease to reduce the risk of cardiac events. The EUROPA trial demonstrated a 20 percent reduction in cardiovascular endpoints in patients with stable coronary artery disease treated with perindopril. The perindopril-indapamide combination is approved for hypertension and for reducing the risk of recurrent stroke in patients with previous stroke or TIA (PROGRESS trial). In diabetic patients, the combination also reduces progression of diabetic nephropathy (ADVANCE trial).
Dosage and Administration
For hypertension: starting dose of 4 mg once daily, increased to 8 mg once daily after four weeks if needed. For heart failure: starting dose of 2 mg once daily under close medical supervision, uptitrated to the maximum tolerated dose of 8 to 16 mg depending on formulation. For stable CAD: 4 to 8 mg once daily. Perindopril should be taken in the morning before breakfast. Dose reduction is required in elderly patients and those with renal impairment (creatinine clearance below 60 mL/min). Perindopril erbumine and perindopril arginine are two salt forms with different dose equivalences (5 mg arginine = 4 mg erbumine).
Side Effects
Dry cough is the most common adverse effect, occurring in 10 to 20 percent of patients and is caused by bradykinin accumulation in the airways. It is more common in women and in patients of East Asian descent. The cough is non-productive, persistent, and resolves within four weeks of stopping the drug. Hypotension, particularly first-dose hypotension, is most pronounced in volume-depleted patients, those on diuretics, or with high-renin states. Hyperkalaemia can develop, especially with concurrent use of potassium-sparing diuretics or in patients with renal impairment. Angioedema is rare (0.1 to 0.5 percent) but potentially life-threatening; it involves bradykinin-mediated swelling of the lips, tongue, or larynx. Renal function deterioration may occur in patients with bilateral renal artery stenosis.
Interactions
Dual RAAS blockade (combination with ARBs, aliskiren, or other ACE inhibitors) is contraindicated due to increased risk of hypotension, hyperkalaemia, and renal failure. NSAIDs reduce the antihypertensive effect and increase the risk of renal impairment. Potassium supplements and potassium-sparing diuretics increase hyperkalaemia risk. Lithium levels may increase with concurrent ACE inhibitor use, requiring monitoring. Antidiabetics including insulin and metformin may have enhanced hypoglycaemic effect when combined with ACE inhibitors. Allopurinol and cytostatics combined with ACE inhibitors increase the risk of haematological toxicity.
Special Notes
Perindopril is absolutely contraindicated during pregnancy (causes oligohydramnios, renal dysgenesis, and foetal death) and should be avoided in breastfeeding. All women of childbearing potential must use effective contraception. Angioedema is a life-threatening emergency requiring immediate epinephrine and airway management. Prior angioedema to any ACE inhibitor is a contraindication to all ACE inhibitors. ACE inhibitors are first-line therapy in hypertension, particularly in diabetic patients with proteinuria, in patients with heart failure, and post-myocardial infarction.
Related Topics
Frequently Asked Questions
Why do ACE inhibitors cause cough?
ACE inhibitors block the breakdown of bradykinin in the lungs. Accumulated bradykinin stimulates sensory C-fibre afferents in the airway mucosa, triggering a persistent dry cough. This effect is class-wide and does not resolve with dose reduction. Switching to an ARB eliminates the cough as ARBs do not affect bradykinin metabolism.
What is the difference between perindopril erbumine and perindopril arginine?
These are two different salt forms of perindopril. Perindopril arginine (Coversyl Arginine) is more stable and has a different dose equivalence: 5 mg arginine is equivalent to 4 mg erbumine, and 10 mg arginine is equivalent to 8 mg erbumine. Prescribers and pharmacists should be aware of this difference to avoid dosing errors when switching formulations.
Can perindopril be used after a heart attack?
Yes, ACE inhibitors including perindopril are recommended in post-MI patients, especially those with left ventricular dysfunction or heart failure. They prevent adverse cardiac remodelling, reduce recurrent MI risk, and improve survival. Treatment should generally start within 24 hours of an uncomplicated MI in haemodynamically stable patients.
Sources
- Fox KM: EUROPA Trial. Lancet 2003
- ESC Heart Failure Guidelines 2023
- ESC Hypertension Guidelines 2023